Preimplantation genetic diagnosis, over the past few years, has been used for detecting chromosomal aneuploidy in patients who undergo in-vitro fertilization. Currently, due to advancements in medical technology, preimplantation genetic diagnosis is being used for detecting a range of indications including chromosomal aberrations, gender, genetic abnormalities, HLA typing, single gene diseases, and X-linked diseases. Demand for preimplantation genetic diagnosis is constantly increasing among individuals who undergo IVF, since it reduces the chances of genetic disorders and disabilities arising in the child and improves the likelihood of live birth. The combination of preimplantation genetic diagnosis and IVF has minimized the chances of passing on harmful genetic materials to the embryo, thus improving the chances of successful pregnancy.
Browse the full Global Preimplantation Genetic Diagnosis Market report at http://www.mrrse.com/preimplantation-genetic-diagnosis-market
Preimplantation genetic diagnosis is performed for the screening of various medical conditions. The global preimplantation genetic diagnosis market is segmented on the basis of geography and type of test. By type of test, the global preimplantation genetic diagnosis market is classified into PGD for chromosomal aberrations, X-linked diseases, HLA typing, gender selection, aneuploidy screening, and single gene disorder. The PGD for aneuploidy segment dominated the global preimplantation genetic diagnosis market in 2013. Aneuploidy screening helps reduce the possibility of creating an embryo with chromosomal abnormalities. The use of fluorescent in situ hybridization and array comparative genomic hybridization technique in preimplantation genetic diagnosis is expected to improve the rate of successful pregnancy.
The demand for preimplantation genetic diagnosis depends on the rules and regulations governing various infertility procedures in numerous countries across the globe. Preimplantation genetic diagnosis for gender selection is banned in most Asian countries and regulated in the United States and Europe. Regulatory impacts are expected to play an important role in the development of the global preimplantation genetic diagnosis market in the years to come. Factors such as the high cost of gender selection process and increasing demand for gender selection by mothers are expected to support the growth of the PGD in gender selection segment in the coming few years.
The increasing awareness among patients about the advantages of using preimplantation genetic diagnosis is expected to propel the global preimplantation genetic diagnosis market in the years to come. The rising occurrence of genetic disorders is further expected to contribute to the growth of the global preimplantation genetic diagnosis market in the next few years. Based on geography, the global preimplantation genetic diagnosis market is divided into North America, Asia Pacific, Europe, and Rest of the World. In 2013, in terms of revenue, the global preimplantation genetic diagnosis market was dominated by Europe, followed by North America. Due to the increasing number of IVF cycles and the increasing disability rate, the North America PGD market is predicted to grow at the fastest CAGR in the years to come.
The global preimplantation genetic diagnosis market is highly fragmented and competitive in nature. Entry of new companies is expected to increase the level of competition in the next few years. Some of the leading players operating in the global preimplantation genetic diagnosis market are Genesis Genetics, Illumina, Inc., Laboratory Corporation of America Holdings, PerkinElmer, Inc., Reprogenetics LLC, Reproductive Genetics Institute, Genea Ltd., Laboratory Corporation of America Holdings, and Quest Diagnostics, Inc.